Ekso Bionics Holdings Inc
F:23E2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Ekso Bionics Holdings Inc
F:23E2
|
US |
|
Iss A/S
OTC:ISFFF
|
DK |
|
D
|
Denso Corp
XBER:DNO
|
JP |
|
K
|
Kennametal Inc
SWB:KM3
|
US |
|
Avalo Therapeutics Inc
F:C6K0
|
US |
|
Maximus Inc
NYSE:MMS
|
US |
|
ArcelorMittal SA
OTC:AMSYF
|
LU |
|
W
|
Western Digital Corp
XMUN:WDC
|
US |
|
K
|
Kosmos Energy Ltd
F:KOS1
|
US |
|
N
|
Northrop Grumman Corp
SWB:NTH
|
US |
|
T
|
Teck Resources Ltd
SWB:TPT
|
CA |
|
IHI Corp
TSE:7013
|
JP |
|
Micron Technology Inc
NASDAQ:MU
|
US |
|
H
|
Hyatt Hotels Corp
SWB:1HTA
|
US |
|
Mitrabara Adiperdana Tbk PT
IDX:MBAP
|
ID |
|
Nexgen Energy Ltd
TSX:NXE
|
CA |
|
MSC Industrial Direct Co Inc
NYSE:MSM
|
US |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
US |
|
S
|
Schumag AG
XHAM:SCM
|
DE |
|
I
|
International Consolidated Airlines Group SA
F:INR
|
UK |
|
T
|
Telefonaktiebolaget LM Ericsson
XBER:ERCG
|
SE |
|
Unilever PLC
LSE:ULVR
|
UK |
|
A
|
Allegion PLC
SWB:60A
|
IE |
|
A
|
American Campus Communities Inc
F:FGA
|
US |
Ekso Bionics Holdings Inc
Ekso Bionics makes wearable robotic exoskeletons that help people move and lift more safely. Its main products are medical exoskeletons used in rehabilitation and therapy, and industrial exoskeletons used on the job to reduce strain on workers. The company sells into two broad markets: hospitals and rehab centers on one side, and employers in construction, manufacturing, and other physically demanding jobs on the other. The business makes money mainly by selling or placing these devices with customers, along with related software, training, and service support. In healthcare, the company’s systems are used by therapists and clinicians to help patients practice walking and mobility after injury or illness. In industry, the products are used to support workers during repetitive or overhead tasks and to lower the risk of injury. What makes Ekso Bionics different is that it sits at the intersection of robotics, medical rehabilitation, and workplace safety. Instead of selling general-purpose robots, it sells a very specific tool that adds physical support to a person’s body. That gives the company a niche role in the value chain: it turns advanced robotics into practical equipment for patient recovery and for reducing physical strain in hard labor environments.
Ekso Bionics makes wearable robotic exoskeletons that help people move and lift more safely. Its main products are medical exoskeletons used in rehabilitation and therapy, and industrial exoskeletons used on the job to reduce strain on workers. The company sells into two broad markets: hospitals and rehab centers on one side, and employers in construction, manufacturing, and other physically demanding jobs on the other.
The business makes money mainly by selling or placing these devices with customers, along with related software, training, and service support. In healthcare, the company’s systems are used by therapists and clinicians to help patients practice walking and mobility after injury or illness. In industry, the products are used to support workers during repetitive or overhead tasks and to lower the risk of injury.
What makes Ekso Bionics different is that it sits at the intersection of robotics, medical rehabilitation, and workplace safety. Instead of selling general-purpose robots, it sells a very specific tool that adds physical support to a person’s body. That gives the company a niche role in the value chain: it turns advanced robotics into practical equipment for patient recovery and for reducing physical strain in hard labor environments.
Revenue Miss: Q2 2025 revenue fell to $2.1 million from $5 million in Q2 2024 due to delays in multi-device Enterprise Health sales, which management views as temporary.
Margin Pressure: Gross margin dropped to 40% from 53% a year ago, primarily due to fixed costs on lower sales volume and increased distribution and shipping costs.
Expense Control: Operating expenses declined 4% year-over-year to $4.8 million, reflecting some cost discipline.
Personal Health Growth: Revenues from Ekso Indego Personal grew over 50% in the first half of 2025, partially offsetting declines in the legacy Enterprise Health segment.
Deferred Sales Pipeline: Management expects to close most of the $1.4 million in delayed Enterprise Health deals before year-end, with a major $1 million order targeted for Q3.
AI & Innovation: The company is investing in AI, launching a new partnership with NVIDIA Connect and revealing an AI voice agent for its flagship device.
Guidance Maintained: Despite Q2 weakness, management remains confident about a stronger second half and sees growing contribution from Personal Health products.
